Professor Dilip Nathwani, OBE, FRCP
Professor Nathwani is a Consultant in Infectious Diseases and Honorary Professor of Infection at the University of Dundee. He is also Director of the Academic Health Sciences Partnership in Tayside, Scotland and led the Scottish Antimicrobial Prescribing Group, a national antimicrobial [AMR] programme, between 2008-2017. He was Chair of the European Study Group on Antibiotic Policies and President of the British Society for Antimicrobial Chemotherapy [BSAC] between 2015-2018. In addition, he is an advisor on AMR to a number of governmental and non-governmental organisations, including WHO, and has led the creation of a range of innovative e-learning resources on AMR. Professor Nathwani has authored more than 260 publications with key areas of interest in AMR, clinical infection management and value-based evaluation of new anti-infectives, connecting global academics and clinical communities to tackle AMR.
Professor David Livermore, PhD
Professor Livermore gained his BSc in 1978 and PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 then joined the Public Health Laboratory Service (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In 2011 he was appointed to his current position as Professor of Medical Microbiology at the University of East Anglia (UEA). Until a partial retirement in 2018 he also had sessions supplied to Public Health England as its Lead on Antibiotic Resistance. Professor Livermore has a long track record of research and publication on the evolution and epidemiology of antibiotic resistance, particularly beta-lactamases. At PHE he tracked the rise of many emerging resistance types, from MRSA to carbapenemase producers. At UEA his work centres upon rapid detection of antibiotic resistance as a means to refining antibiotic stewardship. Professor Livermore has edited for several journals and serves on the Government’s Antimicrobial Resistance Healthcare Associated Infection Advisory Committee. Outside work he enjoys walking and has completed, over 20 years, the entire 3000-mile perimeter of England and more than half of Wales.
Immunology and Strategy
Damian Marron (Strategic and Transactional advisory)
Damian is a successful biotech CEO with a track record of transactional value creation and he is now acting as a non-Executive Director and corporate advisor to Centauri. He has previously completed deals with top-ten pharma through to biotechs including M&A, fundraisings, licensing, and collaborations. He has held operational roles at Agalimmune (CEO, exit via sale), TxCell (CEO, exit via IPO), Cytheris (CEO, asset sale), Trophos (CEO, exit via sale), NicOx (Exec. VP Corp. Dev.), 3M Pharma (Head EU BD), Orphan Europe, Rhone-Poulenc-Rorer and GlaxoSmithKline. His background encompasses basic research and clinical development through to sales and strategic marketing.
Ron Gladue (Immunology and Allergy consultant)
Ron's consultancy role specifically contributes to the design and implementation of the company’s plans, including how to determine the immune efficacy in preclinical models and how to risk-manage potential immunotoxicity. Ron is an accomplished pharmaceutical scientific leader with over 34 years of experience in drug discovery and development for immunological diseases. He has held several positions of increasing responsibility at Pfizer Inc. including Head of Immunology Research; has published over 40 papers in Immunology; is a co-author on over a dozen patents, and has given over 50 presentations at national and international meetings. He currently serves as an advisor to several pharmaceutical companies and foundations including End Allergies Together Foundation; he is also on the editorial staff of Mediators of Inflammation.
Anthony Kong, PhD, FRCR, MRCP
Dr Kong is a reader at King's College London and an honorary NHS consultant clinical oncologist at Guy's and St Thomas' Hospitals NHS trust. He was previously a clinical senior lecturer at University of Birmingham and a clinician scientist at University of Oxford. He has been a principal investigator for numerous early and late clinical trials in breast cancer and head and neck cancers, including immunotherapy trials. Anthony is conducting translational research in relation to resistance mechanisms and biomarkers of various HER/ErbB inhibitors and immunotherapy in breast and head and neck cancers.
Professor Tim Elliott, FRSB, FMedSci, BA, PhD
Professor Elliott is Professor of Experimental Medicine at the University of Southampton. His research encompasses themes within the biology of antigen processing and presentation and immunity to tumours. He is a fellow of the Royal Society of Biology and the Academy of Medical Sciences; Chair of the CRUK Expert Review Panel for Cancer Immunology and member of Science Committee and Co-Chair of the Wellcome Trust Expert Review Group 4, Leukaemia & Lymphoma Research. Professor Elliott is also a member of the scientific advisory board of the Groningen Medical Centre, The Netherlands.